CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

Inclusion Criteria:

   - Must have a human leukocyte antigen (HLA)-matched or single allele-mismatched adult
   sibling serving as donor

   - Must have a myeloid or lymphoid malignant disease that is treated with TLI and ATG
   reduced intensity conditioning for allogeneic transplant (any of the following AML,
   myelodysplastic syndrome [MDS], myeloproliferative disease [MPD], CLL, B or T-cell
   NHL, HL)

   - Patients who due to age, pre-existing medical conditions, or, prior therapy are
   considered to be at high risk for regimen related toxicity associated with fully
   ablative transplant conditioning, and therefore reduced intensity conditioning is
   recommended

   - Ability to understand and the willingness to sign a written informed consent document;
   patients must have signed informed consent to participate in the trial

   - DONOR: Must be an HLA-matched or single allele mismatched sibling of enrolled
   transplant patient

   - DONOR: Must be 18-75 years of age, inclusive

   - DONOR: Must be in a state of general good health and have completed a donor evaluation
   with history, medical examination and standard blood tests within 35 days of starting
   the hematopoietic cell collection procedure; in order to fairly represent the
   interests of the donor, the donor evaluation and consent will be performed by a study
   team member other than the recipient's attending physician

   - DONOR: Must have a white blood cell count > 3.5 x 10^9/liter, platelets > 150 x
   10^9/liter and hematocrit > 35%

   - DONOR: Must be capable of undergoing leukapheresis

   - DONOR: Must be able to understand and sign informed consent

   - DONOR: Must not be seropositive for HIV 1 and 2, hepatitis B surface antigen,
   hepatitis C antibody, human T-lymphotropic virus (HTLV) antibody, cytomegalovirus
   (CMV) immunoglobulin M (IgM), or rapid plasma reagin (RPR) (Treponema); donors with
   prior evidence of hepatitis B core antibody positivity will have a polymerase chain
   reaction (PCR) test done to evaluate for hepatitis B infection; donors with a positive
   hepatitis B PCR test are excluded

   - DONOR: Females must not be pregnant or lactating

   - DONOR: Must not have psychological traits or psychological or medical conditions which
   make them unlikely to tolerate the procedure

   - DONOR: Must not have developed a new malignancy requiring chemotherapy or radiation in
   the interval since apheresis for initial hematocrit (HCT)

   - PATIENT CRITERIA FOR PROCEEDING WITH CD8+ MEMORY T-CELL INFUSION:

   - Patients must be beyond day 30 and before day 60 after transplant

   - Patients must have evidence of mixed CD3 T-cell chimerism based on the day +28 (+/- 7
   days) blood sample showing >= 5% and =< 95% donor type cells

   - Patients must have no evidence of active graft-versus-host disease at the time of the
   CD8+ memory T-cell infusion; patients with a history of acute GVHD overall grade II
   based on skin only involvement or upper gastrointestinal (GI) tract involvement only
   will be eligible; patients with a history of liver or lower GI tract GVHD will not be
   eligible

   - Patients must be on single immune suppression therapy with either tacrolimus or
   cyclosporine at the time of CD8+ memory T-cell infusion; prednisone at a physiologic
   dose of 5 mg per day or less is allowed

   - Patients must have a Karnofsky performance status of >= 60% at the time of the CD8+
   memory T-cell infusion

   - Patients must not have an uncontrolled bacterial, fungal or viral infection, defined
   as progressive symptoms despite therapy, at the time of the CD8+ memory T-cell
   infusion; asymptomatic viremia is allowed

   - Patients must have adequate organ function and performance status at the time of the
   CD8+ memory T-cell infusion, defined by the following:

      - Total bilirubin =< 4 mg/dL

      - SGOT or SGPT =< 4 x ULN

      - Creatinine =< 3 mg/dL or estimated creatinine clearance >= 40ml/min

Exclusion Criteria:

   - Uncontrolled bacterial, viral or fungal infection defined as currently taking
   medication and progression of clinical symptoms

   - Progressive hemato-lymphoid malignancy despite conventional therapy

   - Acute leukemia not in remission

   - Chronic myelogenous leukemia (CML)

   - Active central nervous system (CNS) involvement of the underlying malignancy

   - Human immunodeficiency virus (HIV) positive

   - Pregnant or lactating

   - Prior malignancy (EXCEPTION: diagnosed > 5 years ago without evidence of disease, OR
   treated =< 5 years ago but have a greater than 50% chance of life expectancy of >= 5
   years for that malignancy)

   - Have a psychiatric disorder(s) or psychosocial circumstance(s) which in the opinion of
   the primary physician would place the patient at an unacceptable risk from transplant

   - Ejection fraction < 30%, or uncontrolled cardiac failure

   - Diffusing capacity of the lung for carbon monoxide (DLCO) < 40% predicted

   - Total bilirubin > 3 mg/dL

   - Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate
   transaminase (SGPT) > 4 x upper limit of normal (ULN)

   - Creatinine > 2 mg/dL and an estimated creatinine clearance =< 40 mL/min

   - Poorly controlled hypertension despite multiple antihypertensive medication OR

   - Karnofsky performance status (KPS) < 60%

   - Note: Patients positive for hepatitis B and C will be evaluated on a case by case
   basis